Figure 4. Effect of GSK2141795 on FDG uptake in SKOV3 monolayer, spheroids and mouse xenografts.

Time-course of [³H]FDG uptake in SKOV3 monolayers (N = 3) A. and spheroids (N = 3, experiments performed in triplicate ± SEM) B. pre-incubated with either vehicle or GSK2141795 (1 and 5 μM) for 48 hours; Dose-dependent effect of GSK2141795 on the uptake of [³H]FDG into SKOV3 monolayers following 2 hours incubation with [³H]FDG; SKOV3 spheroids following 2 and 6 hours incubation with [³H]FDG (N = 3, experiments performed in triplicate ± SEM) C.; and uptake of [¹⁸F]FDG into tumours of SKOV3 xenografted mice following 5 hours drug treatment (10 - 30 mg/Kg; n = 3 per dose except for 20 mg/Kg where n = 1), *p < 0.05 compared to vehicle treated animals (unpaired t-test) D.. Pearson correlation between expression levels of phospho-PRAS40 (Thr246) and [³H]FDG uptake into SKOV3 monolayers E. and spheroids F. following treatment with GSK2141795. SKOV3 monolayers and spheroids were treated with varying concentrations of GSK2141795 for 48 hours. Phospho-PRAS40 (Thr246) and [³H]FDG uptake were analysed as described in the methods section. Abbreviations: DPM = decays per minute; SUV = standardised uptake values; AUC = area under the curve.